AGTC to Present at the Wedbush PacGrow Healthcare Conference on August 15, 2018
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Aug. 08, 2018 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that Sue Washer, President and Chief Executive Officer, will present at the Wedbush PacGrow Healthcare Conference on Wednesday, August 15th, 2018 at 9:45 am ET in New York.
A live audio webcast of the presentation can be accessible by visiting ir.agtc.com/events-and-presentations. A replay will be available on the company's website following the event.
About AGTC
AGTC is a clinical-stage biotechnology company that uses a proprietary gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. Its initial focus is in the field of ophthalmology, where it has active clinical trials in X-linked retinoschisis (XLRS), X-linked retinitis pigmentosa (XLRP), and achromatopsia (ACHM CNGB3 & ACHM CNGA3). In addition to its clinical trials, AGTC has preclinical programs in optogenetics, adrenoleukodystrophy (ALD), which is a disease of the central nervous system (CNS), and otology. The clinical-stage XLRS and XLRP programs, the discovery program in ALD and two additional ophthalmology programs are being developed in collaboration with Biogen, and the optogenetics program is being developed in collaboration with Bionic Sight. In addition to its product pipeline, AGTC has a significant intellectual property portfolio and extensive expertise in the design of gene therapy products including capsids, promoters and expression cassettes, as well as expertise in the formulation, manufacture and physical delivery of gene therapy products.
IR/PR CONTACTS: David Carey (IR) or Tom Vickery (PR) Lazar Partners Ltd. T: (212) 867-1768 or (646) 871-8482 [email protected] or [email protected]
Corporate Contact: Bill Sullivan Chief Financial Officer Applied Genetic Technologies Corporation T: (617) 843-5728 [email protected]
Stephen Potter Chief Business Officer Applied Genetic Technologies Corporation T: (617) 413-2754 [email protected]